

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

34. (Currently Amended) Isolated nucleic acid encoding a humanized variant of a parent anti-VEGF antibody which parent antibody comprises non-human variable domains, wherein said humanized variant binds human VEGF and comprises the following heavy chain Complementary Determining Region (CDR) amino acid sequences: SEQ ID NO:128 as CDRH1, SEQ ID NO:2 as CDRH2 and SEQ ID NO:129 as CDRH3:

~~—— (a) binds human VEGF with a K_d value of no more than about 1×10^{-8} M, said K_d value being no more than about 6 fold of the K_d value of said parent antibody;~~

~~—— (b) has an ED50 value of no more than about 5nM for inhibiting VEGF-induced proliferation of endothelial cells *in vitro*; and~~

~~—— (c) inhibits VEGF-induced angiogenesis *in vivo*, wherein 5mg/kg of said humanized variant inhibits at least about 50% of tumor growth in an A673 *in vivo* tumor model.~~

35. (Previously presented) A vector comprising the nucleic acid of claim 34.

36. (Previously presented) A host cell comprising the vector of claim 35.

37. (Previously presented) A process of producing a humanized anti-VEGF antibody comprising culturing the host cell of claim 36 so that the nucleic acid is expressed.

38. (Previously presented) The process of claim 37 further comprising recovering the humanized anti-VEGF antibody from the host cell culture.

Please add the following new claims: (number following non-elected claims 39-42)

43. (NEW) The isolated nucleic acid of claim 34, wherein the humanized variant further comprises the following light chain Complementary Determining Region (CDR) amino acid sequences: SEQ ID NO:4 as CDRL1, SEQ ID NO:5 as CDRL2 and SEQ ID NO:6 as CDRL3.

OK 44. (NEW) The isolated nucleic acid of claim 43, wherein the humanized variant comprises a heavy chain variable domain sequence of SEQ ID NO:7 and a light chain variable domain sequence of SEQ ID NO:8.

OK 45. (NEW) The isolated nucleic acid of claim 43, wherein the humanized variant comprises a heavy chain variable domain sequence of SEQ ID NO:116 and a light chain variable domain sequence of SEQ ID NO:115.

46. (NEW) The isolated nucleic acid of claim 34, wherein the humanized variant comprises a heavy chain variable domain sequence of SEQ ID NO:125. — CDR NOT VARIABLE domain

47. (NEW) The isolated nucleic acid of claim 43, wherein the humanized variant comprises a light chain variable domain sequence of SEQ ID NO:124. — CDR

OK 48. (NEW) The isolated nucleic acid of claim 34, wherein the humanized variant comprises a CDRH1 sequence of SEQ ID NO:1.

UPPER CASE domain NOT JUST CDR 49. (NEW) The isolated nucleic acid of claim 34, wherein the humanized variant comprises a CDRH1 sequence of SEQ ID NO:126. — LIGHT CHAIN

50. (NEW) The isolated nucleic acid of claim 34, wherein the humanized variant comprises a CDRH3 sequence of SEQ ID NO:3.

51. (NEW) The isolated nucleic acid of claim 34, wherein the humanized variant comprises a CDRH3 sequence of SEQ ID NO:127. — VARIANTE REGION NOT CDR HEAVY CHAIN

APPENDIX
Clean Set of All Pending Claims

D1
34. Isolated nucleic acid encoding a humanized variant of a parent anti-VEGF antibody which parent antibody comprises non-human variable domains, wherein said humanized variant binds human VEGF and comprises the following heavy chain Complementary Determining Region (CDR) amino acid sequences: SEQ ID NO:128 as CDRH1, SEQ ID NO:2 as CDRH2 and SEQ ID NO:129 as CDRH3.

35. A vector comprising the nucleic acid of claim 34.

36. A host cell comprising the vector of claim 35.

37. A process of producing a humanized anti-VEGF antibody comprising culturing the host cell of claim 36 so that the nucleic acid is expressed.

38. The process of claim 37 further comprising recovering the humanized anti-VEGF antibody from the host cell culture.

43. The isolated nucleic acid of claim 34, wherein the humanized variant further comprises the following light chain Complementary Determining Region (CDR) amino acid sequences: SEQ ID NO:4 as CDRL1, SEQ ID NO:5 as CDRL2 and SEQ ID NO:6 as CDRL3.

D2
44. The isolated nucleic acid of claim 43, wherein the humanized variant comprises a heavy chain variable domain sequence of SEQ ID NO:7 and a light chain variable domain sequence of SEQ ID NO:8.

45. The isolated nucleic acid of claim 43, wherein the humanized variant comprises a heavy chain variable domain sequence of SEQ ID NO:116 and a light chain variable domain sequence of SEQ ID NO:115.

46. The isolated nucleic acid of claim 34, wherein the humanized variant comprises a heavy chain variable domain sequence of SEQ ID NO:125.

47. The isolated nucleic acid of claim 43, wherein the humanized variant comprises a light chain variable domain sequence of SEQ ID NO:124.

48. The isolated nucleic acid of claim 34, wherein the humanized variant comprises a CDRH1 sequence of SEQ ID NO:1.

D²
49. The isolated nucleic acid of claim 34, wherein the humanized variant comprises a CDRH1 sequence of SEQ ID NO:126.

50. The isolated nucleic acid of claim 34, wherein the humanized variant comprises a CDRH3 sequence of SEQ ID NO:3.

51. The isolated nucleic acid of claim 34, wherein the humanized variant comprises a CDRH3 sequence of SEQ ID NO:127.

